Abstract
The term “cancer stem cells” (CSCs) refers to cancer cells that exhibit traits parallel to normal stem cells, namely the potential to give rise to every type of cell identified in a tumor microenvironment. It has been found that CSCs usually develops from other neoplastic cells or non-cancerous somatic cells by acquiring stemness and malignant characteristics through particular genetic modifications. A trivial number of CSCs, identified in solid and liquid cancer, can give rise to an entire tumor population with aggressive anticancer drug resistance, metastasis, and invasiveness. Besides, cancer stem cells manipulate their intrinsic and extrinsic features, regulate the metabolic pattern of the cell, adjust efflux-influx efficiency, modulate different signaling pathways, block apoptotic signals, and cause genetic and epigenetic alterations to retain their pluripotency and ability of self-renewal. Notably, to keep the cancer stem cells’ ability to become malignant cells, mesenchymal stem cells, tumor-associated fibroblasts, immune cells, etc., interact with one another. Furthermore, CSCs are characterized by the expression of particular molecular markers that carry significant diagnostic and prognostic significance. Because of this, scientific research on CSCs is becoming increasingly imperative, intending to understand the traits and behavior of cancer stem cells and create more potent anticancer therapeutics to fight cancer at the CSC level. In this review, we aimed to elucidate the critical role of CSCs in the onset and spread of cancer and the characteristics of CSCs that promote severe resistance to targeted therapy.
Graphical Abstract
Similar content being viewed by others
Data Availability
Dataset used in this study will be available as per request (mailing to the corresponding author).
Code Availability
Not Applicable
References
WHO. (2022). Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
Nimmakayala, R. K., Batra, S. K., & Ponnusamy, M. P. (2019). Unraveling the journey of cancer stem cells from origin to metastasis. Biochimica et Biophysica Acta - Reviews on Cancer, 1871(1), 50–63.
Zhu, P., & Fan, Z. (2018). Cancer stem cells and tumorigenesis. Biophys Rep, 4(4), 178–188.
Nowell, P. C. (1976). The clonal evolution of tumor cell populations. Science, 194(4260), 23–28.
Safa, A. R., et al. (2015). Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes & Diseases, 2(2), 152–163.
Chen, W., et al. (2016). Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells International, 2016, 1740936.
Hadjimichael, C., et al. (2015). Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells, 7(9), 1150–1184.
Dontu, G., et al. (2003). Stem cells in normal breast development and breast cancer. Cell Proliferation, 36(Suppl 1), 59–72.
Zhang, K., et al. (2017). WNT/β-catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells. Cancer Research, 77(9), 2534–2547.
Clement, V., et al. (2007). HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Current Biology, 17(2), 165–172.
Bradford, G. B., et al. (1997). Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Experimental Hematology, 25(5), 445–453.
Glauche, I., et al. (2009). Stem cell proliferation and quiescence–two sides of the same coin. PLoS Computational Biology, 5(7), e1000447.
Goss, P. E., & Chambers, A. F. (2010). Does tumour dormancy offer a therapeutic target? Nature Reviews Cancer, 10(12), 871–877.
Mohr, M., Zänker, K. S., & Dittmar, T. (2015). Cancer (stem) cell differentiation: An inherent or acquired property? Medical Hypotheses, 85(6), 1012–1018.
Yang, L., et al. (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy, 5(1), 8.
Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741–4751.
Lobo, N. A., et al. (2007). The biology of cancer stem cells. Annual Review of Cell and Developmental Biology, 23, 675–699.
Lapidot, T., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367(6464), 645–648.
Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.
Tang, C., Ang, B. T., & Pervaiz, S. (2007). Cancer stem cell: Target for anti-cancer therapy. The FASEB Journal, 21(14), 3777–3785.
Al-Hajj, M., et al. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), 3983–3988.
Joshua, B., et al. (2012). Frequency of cells expressing CD44, a head and neck cancer stem cell marker: Correlation with tumor aggressiveness. Head and Neck, 34(1), 42–49.
O’Brien, C. A., et al. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 106–110.
Quintana, E., et al. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456(7222), 593–598.
Singh, S. K., et al. (2004). Identification of human brain tumour initiating cells. Nature, 432(7015), 396–401.
Kong, Y., et al. (2008). CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia, 22(6), 1207–1213.
Rich, J. N. (2016). Cancer stem cells: Understanding tumor hierarchy and heterogeneity. Medicine (Baltimore), 95(1 Suppl 1), S2-s7.
Ye, F., et al. (2015). The presence of EpCAM(-)/CD49f(+) cells in breast cancer is associated with a poor clinical outcome. Journal of Breast Cancer, 18(3), 242–248.
Yang, L., et al. (2015). LGR5 promotes breast cancer progression and maintains stem-like cells through activation of Wnt/β-catenin signaling. Stem Cells, 33(10), 2913–2924.
Kong, Y., et al. (2018). Breast cancer stem cell markers CD44 and ALDH1A1 in serum: Distribution and prognostic value in patients with primary breast cancer. Journal of Cancer, 9(20), 3728–3735.
Hiraga, T., Ito, S., & Nakamura, H. (2016). EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation. International Journal of Cancer, 138(7), 1698–1708.
Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nature Reviews Cancer, 8(10), 755–768.
Zheng, Y., et al. (2022). Lung cancer stem cell markers as therapeutic targets: An update on signaling pathways and therapies. Frontiers in Oncology, 12, 873994.
Yan, X., et al. (2013). Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncology Reports, 30(6), 2733–2740.
Sakabe, T., et al. (2017). CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer. Oncology Letters, 13(5), 3703–3708.
Kubo, T., Takigawa, N., Osawa, M., Harada, D., Ninomiya, T., Ochi, N., et al. (2013). Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Science, 104(1), 78–84. https://doi.org/10.1111/cas.12045
Eramo, A., et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 15(3), 504–514.
Zhou, Y., et al. (2018). Cancer stem cells in progression of colorectal cancer. Oncotarget, 9(70), 33403–33415.
Fedyanin, M., et al. (2017). Role of stem cells in colorectal cancer progression and prognostic and predictive characteristics of stem cell markers in colorectal cancer. Current Stem Cell Research & Therapy, 12(1), 19–30.
Tsochantaridis, I., et al. (2023). The concept of cancer stem cells: Elaborating on ALDH1B1 as an emerging marker of cancer progression. Life, 13(1), 197.
Sottoriva, A., et al. (2010). Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Research, 70(1), 46–56.
Kenny, H. A., et al. (2014). Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. The Journal of Clinical Investigation, 124(10), 4614–4628.
Lathia, J. D., et al. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203–1217.
Muto, J., et al. (2012). RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathways. PLoS One, 7(3), e33431.
Read, T. A., et al. (2009). Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell, 15(2), 135–147.
Yan, X., et al. (2011). A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proceedings of the National Academy of Sciences, 108(4), 1591–1596.
Kaaijk, P., et al. (1995). Expression of CD44 splice variants in human primary brain tumors. Journal of Neuro-Oncology, 26(3), 185–190.
Bao, S., et al. (2008). Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Research, 68(15), 6043–6048.
Bao, S., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760.
Gao, X., et al. (2012). Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. Cancer Research, 73(5), 1481–1490.
Monzani, E., et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. European Journal of Cancer, 43(5), 935–946.
Wilson, B. J., et al. (2014). ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Research, 74(15), 4196–4207.
Parmiani, G. (2016). Melanoma cancer stem cells: Markers and functions. Cancers (Basel), 8(3).
Klein, W. M., et al. (2007). Increased expression of stem cell markers in malignant melanoma. Modern Pathology, 20(1), 102–107.
Kleffel, S., et al. (2015). Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell, 162(6), 1242–1256.
Schatton, T., et al. (2008). Identification of cells initiating human melanomas. Nature, 451(7176), 345–349.
Yu, S. S., & Cirillo, N. (2020). The molecular markers of cancer stem cells in head and neck tumors. Journal of Cellular Physiology, 235(1), 65–73.
Krishnamurthy, S., & Nör, J. E. (2012). Head and neck cancer stem cells. Journal of Dental Research, 91(4), 334–340.
Jakob, M., et al. (2021). Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC. Strahlentherapie und Onkologie, 197(3), 231–245.
Herzog, A. E., et al. (2021). The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death & Disease, 12(11), 988.
Prince, M. E., et al. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences, 104(3), 973–978.
Kersten, B., et al. (2016). CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. British Journal of Haematology, 173(2), 219–235.
Villatoro, A., et al. (2020). Leukemia stem cell release from the stem cell niche to treat acute myeloid leukemia. Frontiers in Cell and Developmental Biology, 8, 607.
Tavernier, E., et al. (2014). CXCR4: A new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia. Bulletin du Cancer, 101(6), 593–604.
Marchand, T., & Pinho, S. (2021). Leukemic stem cells: From leukemic niche biology to treatment opportunities. Frontiers in Immunology, 12, 775128.
Haubner, S., et al. (2019). Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia, 33(1), 64–74.
Ding, Y., Gao, H., & Zhang, Q. (2017). The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investigation, 4, 19.
Zhang, R., et al. (2020). Co-expression of stem cell and epithelial mesenchymal transition markers in circulating tumor cells of bladder cancer patients. Oncotargets and Therapy, 13, 10739–10748.
Wang, L., et al. (2018). Prognostic implication of urothelial stem cell markers differs according to primary tumour location in non-muscle-invasive bladder cancer. Cellular Physiology and Biochemistry, 48(6), 2364–2373.
Siddiqui, Z., et al. (2020). Synergic effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor Nanog, on bladder cancer prognosis. British Journal of Biomedical Science, 77(2), 69–75.
Li, Y., et al. (2017). Bladder cancer stem cells: Clonal origin and therapeutic perspectives. Oncotarget, 8(39), 66668–66679.
Abugomaa, A., et al. (2020) Emerging roles of cancer stem cells in bladder cancer progression, tumorigenesis, and resistance to chemotherapy: A potential therapeutic target for bladder cancer. Cells, 9(1).
Wang, B., et al. (2016). LGR5 is a gastric cancer stem cell marker associated with stemness and the EMT signature genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1. PLoS One, 11(12), e0168904.
Senel, F., et al. (2017). Prognostic value of cancer stem cell markers CD44 and ALDH1/2 in gastric cancer cases. Asian Pacific Journal of Cancer Prevention, 18(9), 2527–2531.
Razmi, M., et al. (2021). Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: A systematic review and meta-analysis. Cancer Cell International, 21(1), 139.
Nosrati, A., Naghshvar, F., & Khanari, S. (2014). Cancer stem cell markers CD44, CD133 in primary gastric adenocarcinoma. Int J Mol Cell Med, 3(4), 279–286.
Fu, Y., Du, P., Zhao, J., Hu, C., Qin, Y., & Huang, G. (2018). Gastric cancer stem cells: Mechanisms and therapeutic approaches. Yonsei Medical Journal, 59(10), 1150–1158. https://doi.org/10.3349/ymj.2018.59.10.1150
Klemba, A., et al. (2018). Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. Contemporary Oncology (Pozn), 22(1a), 48–55.
Ma, S., et al. (2008). Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Molecular Cancer Research, 6(7), 1146–1153.
Sun, J. H., et al. (2016). Liver cancer stem cell markers: Progression and therapeutic implications. World Journal of Gastroenterology, 22(13), 3547–3557.
Qiu, L., et al. (2018). Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC. Oncology Letters, 15(2), 2039–2048.
Haraguchi, N., et al. (2010). CD13 is a therapeutic target in human liver cancer stem cells. The Journal of Clinical Investigation, 120(9), 3326–3339.
Ohara, Y., et al. (2013). Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Cancer Science, 104(8), 1127–1134.
Gzil, A., et al. (2019). Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Molecular Biology Reports, 46(6), 6629–6645.
Fitzgerald, T. L., & McCubrey, J. A. (2014). Pancreatic cancer stem cells: Association with cell surface markers, prognosis, resistance, metastasis and treatment. Advances in Biological Regulation, 56, 45–50.
Mondal, S., Bhattacharya, K., & Mandal, C. (2018). Nutritional stress reprograms dedifferention in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: A stochastic model of cancer stem cells. Cell Death Discovery, 4(1), 110.
Sun, X., et al. (2020). Hypoxia-mediated cancer stem cell resistance and targeted therapy. Biomedicine & Pharmacotherapy, 130, 110623.
Hayama, M., et al. (2016). Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy. Journal of Thoracic Disease, 8(1), 116–123.
Pistritto, G., et al. (2016). Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY), 8(4), 603–619.
Wojtkowiak, J. W., et al. (2011). Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Molecular Pharmaceutics, 8(6), 2032–2038.
Hagelund, S., & Trauzold, A. (2022). Impact of extracellular pH on apoptotic and non-apoptotic TRAIL-Induced signaling in pancreatic ductal adenocarcinoma cells. Frontiers in Cell and Development Biology, 10, 768579.
Sharma, V., et al. (2015). Low-pH-induced apoptosis: Role of endoplasmic reticulum stress-induced calcium permeability and mitochondria-dependent signaling. Cell Stress and Chaperones, 20(3), 431–440.
Plaks, V., Kong, N., & Werb, Z. (2015). The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell, 16(3), 225–238.
Puca, F., et al. (2022). Role of diet in stem and cancer stem cells. International Journal of Molecular Sciences, 23(15).
Smith, A. G., & Macleod, K. F. (2019). Autophagy, cancer stem cells and drug resistance. The Journal of Pathology, 247(5), 708–718.
Tomasetti, C., & Vogelstein, B. (2015). Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science, 347(6217), 78–81.
White, A. C., & Lowry, W. E. (2015). Refining the role for adult stem cells as cancer cells of origin. Trends in Cell Biology, 25(1), 11–20.
Beck, B., & Blanpain, C. (2013). Unravelling cancer stem cell potential. Nature Reviews Cancer, 13(10), 727–738.
Bjerkvig, R., et al. (2005). Opinion: The origin of the cancer stem cell: Current controversies and new insights. Nature Reviews Cancer, 5(11), 899–904.
Lau, E. Y., Ho, N. P., & Lee, T. K. (2017). Cancer stem cells and their microenvironment: Biology and therapeutic implications. Stem Cells Int, 2017, 3714190.
Reya, T., et al. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105–111.
Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23(10), 1124–1134. https://doi.org/10.1038/nm.4409
Valent, P., et al. (2012). Cancer stem cell definitions and terminology: The devil is in the details. Nature Reviews Cancer, 12(11), 767–775.
Cox, C. V., et al. (2004). Characterization of acute lymphoblastic leukemia progenitor cells. Blood, 104(9), 2919–2925.
Al-Mawali, A., Gillis, D., & Lewis, I. (2016). Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. Journal of Hematology & Oncology, 9(1), 61.
Kikushige, Y., & Miyamoto, T. (2015). Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology, 89(Suppl 1), 28–32.
Sun, Q., et al. (2008). Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia. Research, 32(9), 1374–1381.
Tavor, S., et al. (2004). CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Research, 64(8), 2817–2824.
Luo, Y., et al. (2012). ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells, 30(10), 2100–2113.
Fusi, A., et al. (2011). Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. The Journal of Investigative Dermatology, 131(2), 487–494.
Boiko, A. D., et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature, 466(7302), 133–137.
Fang, D., et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research, 65(20), 9328–9337.
Liu, S., et al. (2014). Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports, 2(1), 78–91.
Duru, N., et al. (2016). Characterization of the CD49f+/CD44+/CD24- single-cell derived stem cell population in basal-like DCIS cells. Oncotarget, 7(30), 47511–47525.
Li, C., et al. (2016). GALNT1-mediated glycosylation and activation of sonic hedgehog signaling maintains the self-renewal and tumor-initiating capacity of bladder cancer stem cells. Cancer Research, 76(5), 1273–1283.
Huang, P., et al. (2013). Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line. Molecular and Clinical Oncology, 1(1), 180–184.
Li, X. B., et al. (2016). Gastric Lgr5(+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. Cell Research, 26(7), 838–849.
Brungs, D., et al. (2016). Gastric cancer stem cells: Evidence, potential markers, and clinical implications. Journal of Gastroenterology, 51(4), 313–326.
Wu, W., et al. (2016). Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer. Oncotarget, 7(49), 81144–81155.
Zhang, S. S., Han, Z. P., Jing, Y. Y., Tao, S. F., Li, T. J., Wang, H., et al. (2012). CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Medicine, 10, 85. https://doi.org/10.1186/1741-7015-10-85
Conic, I., Stanojevic, Z., Jankovic Velickovic, L., Stojnev, S., Ristic Petrovic, A., Krstic, M., et al. (2015) Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy. The Journal of Obstetrics and Gynaecology Research, 41(10), 1630–1637. https://doi.org/10.1111/jog.12758
Bhaijee, F., et al. (2012). Cancer stem cells in head and neck squamous cell carcinoma: A review of current knowledge and future applications. Head and Neck, 34(6), 894–899.
Jung, Y. S., et al. (2015). CD200: Association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma. Head and Neck, 37(3), 327–335.
Rozeik, M. S., et al. (2017). Evaluation of CD44 and CD133 as markers of liver cancer stem cells in Egyptian patients with HCV-induced chronic liver diseases versus hepatocellular carcinoma. Electronic Physician, 9(7), 4708–4717.
Yang, Z. F., et al. (2008). Significance of CD90+ cancer stem cells in human liver cancer. Cell, 13(2), 153–166.
Okudela, K., et al. (2012). Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma–their prognostic significance. Pathology International, 62(12), 792–801.
Vaz, A. P., et al. (2014). A concise review on the current understanding of pancreatic cancer stem cells. Journal of Cancer Stem Cell Research, 2.
Hermann, P. C., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323.
Miranda-Lorenzo, I., et al. (2014). Intracellular autofluorescence: A biomarker for epithelial cancer stem cells. Nature Methods, 11(11), 1161–1169.
Kim, N., et al. (2015). Cancer stem cell markers in eyelid sebaceous gland carcinoma: High expression of ALDH1, CD133, and ABCG2 correlates with poor prognosis. Investigative Ophthalmology & Visual Science, 56(3), 1813–1819.
Yanamoto, S., et al. (2014). Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: Effect of neoadjuvant chemotherapy on local recurrence. International Journal of Oncology, 44(4), 1153–1162.
Nagata, T., et al. (2011). Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Research, 31(2), 495–500.
Elbasateeny, S. S., et al. (2016). Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathology, Research and Practice, 212(1), 10–16.
Bi, Y., et al. (2016). Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis. Journal of Surgical Oncology, 113(2), 144–151.
Lukenda, A., et al. (2016). Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma. Journal of Clinical Pathology, 69(3), 234–239.
Tysnes, B. B., & Bjerkvig, R. (2007). Cancer initiation and progression: Involvement of stem cells and the microenvironment. Biochimica et Biophysica Acta, 1775(2), 283–297.
Zhou, B. B., et al. (2009). Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nature Reviews Drug Discovery, 8(10), 806–823.
Thanan, R., et al. (2013). Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radical Biology & Medicine, 65, 1464–1472.
Li, C., et al. (2017). CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. Theranostics, 7(1), 67–80.
Zhao, J. (2016). Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacology & Therapeutics, 160, 145–158.
Chen, X., et al. (2017). Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. Oncotarget, 8(10), 17301–17312.
Boumahdi, S., et al. (2014). SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature, 511(7508), 246–250.
Lu, H., Ouyang, W., & Huang, C. (2006). Inflammation, a key event in cancer development. Molecular Cancer Research, 4(4), 221–233.
Okada, F. (2002). Inflammation and free radicals in tumor development and progression. Redox Report, 7(6), 357–368.
Ohnishi, S., et al. (2013). DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxidative Medicine and Cellular Longevity, 2013, 387014.
Jing, Y., et al. (2012). Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One, 7(8), e43272.
Ma, N., et al. (2011). Nitrative DNA damage and Oct3/4 expression in urinary bladder cancer with Schistosoma haematobium infection. Biochemical and Biophysical Research Communications, 414(2), 344–349.
Thanan, R., et al. (2012). Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators of Inflammation, 2012, 165879.
Logan, C. M., et al. (2007). Prostaglandin E2: At the crossroads between stem cell development, inflammation and cancer. Cancer Biology & Therapy, 6(10), 1517–1520.
Kawanishi, S., Hiraku, Y., & Oikawa, S. (2001). Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging. Mutation Research, 488(1), 65–76.
Cabarcas, S. M., Mathews, L. A., & Farrar, W. L. (2011). The cancer stem cell niche–there goes the neighborhood? International Journal of Cancer, 129(10), 2315–2327.
Lee, G., Hall, R. R. 3rd, & Ahmed A. U. (2016). Cancer stem cells: Cellular plasticity, niche, and its clinical relevance. Journal of Stem Cell Research & Therapy, 6(10).
Quante, M., et al. (2011). Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell, 19(2), 257–272.
Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews Cancer, 16(9), 582–598.
Kitamura, T., Qian, B. Z., & Pollard, J. W. (2015). Immune cell promotion of metastasis. Nature Reviews Immunology, 15(2), 73–86.
Carnero, A., & Lleonart, M. (2016). The hypoxic microenvironment: A determinant of cancer stem cell evolution. BioEssays, 38(Suppl 1), S65-74.
Azuma, T., et al. (2008). B7–H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 111(7), 3635–3643.
Bennewith, K. L., & Durand, R. E. (2004). Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Research, 64(17), 6183–6189.
Brurberg, K. G., et al. (2006). Fluctuations in pO2 in irradiated human melanoma xenografts. Radiation Research, 165(1), 16–25.
Gilbertson, R. J., & Rich, J. N. (2007). Making a tumour’s bed: Glioblastoma stem cells and the vascular niche. Nature Reviews Cancer, 7(10), 733–736.
Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677–684.
Ricciuti, B., et al. (2019). Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. Seminars in Cancer Biology, 56, 87–99.
Folkins, C., et al. (2009). Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Research, 69(18), 7243–7251.
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015), 332–337.
Crawford, Y., & Ferrara, N. (2009). Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends in Pharmacological Sciences, 30(12), 624–630.
Owen, J. L., & Mohamadzadeh, M. (2013). Macrophages and chemokines as mediators of angiogenesis. Frontiers in Physiology, 4, 159.
Maniotis, A. J., et al. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. American Journal of Pathology, 155(3), 739–752.
Yao, X. H., Ping, Y. F., & Bian, X. W. (2011). Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein & Cell, 2(4), 266–272.
Weis, S. M., & Cheresh, D. A. (2011). Tumor angiogenesis: Molecular pathways and therapeutic targets. Nature Medicine, 17(11), 1359–1370.
Bissell, M. J. (1999). Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? The American Journal of Pathology, 155(3), 675–9.
Fausto, N. (2000). Vasculogenic mimicry in tumors. Fact or artifact? The American Journal of Pathology, 156(2), 359.
Folberg, R., Hendrix, M. J., & Maniotis, A. J. (2000). Vasculogenic mimicry and tumor angiogenesis. American Journal of Pathology, 156(2), 361–381.
McDonald, D. M., Munn, L., & Jain, R. K. (2000). Vasculogenic mimicry: How convincing, how novel, and how significant? American Journal of Pathology, 156(2), 383–388.
Shubik, P., & Warren, B. A. (2000). Additional literature on “vasculogenic mimicry” not cited. American Journal of Pathology, 156(2), 736.
Treps, L., Faure, S., & Clere, N. (2021). Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target. Pharmacology & Therapeutics, 223, 107805.
Bussolati, B., et al. (2009). Endothelial cell differentiation of human breast tumour stem/progenitor cells. Journal of Cellular and Molecular Medicine, 13(2), 309–319.
Ricci-Vitiani, L., et al. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 468(7325), 824–828.
Soda, Y., et al. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A, 108(11), 4274–4280.
Wang, R., et al. (2010). Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 468(7325), 829–833.
Gregory, P. A., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593–601.
Hwang, W. L., et al. (2014). MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nature Cell Biology, 16(3), 268–280.
Wang, X., et al. (2013). Krüppel-like factor 8 promotes tumorigenic mammary stem cell induction by targeting miR-146a. American Journal of Cancer Research, 3(4), 356–373.
Mani, S. A., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.
Morel, A. P., et al. (2008). Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 3(8), e2888.
DiMeo, T. A., et al. (2009). A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Research, 69(13), 5364–5373.
Brabletz, T., et al. (2005). Opinion: Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nature Reviews Cancer, 5(9), 744–749.
Masui, T., et al. (2014). Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. International Journal of Oncology, 44(3), 693–699.
Li, J., et al. (2015). Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells. Molecular Medicine Reports, 12(1), 192–198.
Tu, C. C., et al. (2013). Activation of snail and EMT-like signaling via the IKKαβ/NF-κB pathway in Apicidin-resistant HA22T hepatocellular carcinoma cells. Chinese Journal of Physiology, 56(6), 326–333.
Wang, Z., et al. (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research, 69(6), 2400–2407.
Blick, T., et al. (2010). Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. Journal of Mammary Gland Biology and Neoplasia, 15(2), 235–252.
Hollier, B. G., Evans, K., & Mani, S. A. (2009). The epithelial-to-mesenchymal transition and cancer stem cells: A coalition against cancer therapies. Journal of Mammary Gland Biology and Neoplasia, 14(1), 29–43.
Radisky, D. C., & LaBarge, M. A. (2008). Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell, 2(6), 511–512.
Rho, J. K., et al. (2009). Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 63(2), 219–226.
Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., et al. (2005). Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clinical Cancer Research, 11(24 Pt 1), 8686–8698. https://doi.org/10.1158/1078-0432.Ccr-05-1492
Frederick, B. A., et al. (2007). Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Molecular Cancer Therapeutics, 6(6), 1683–1691.
Fuchs, B. C., et al. (2008). Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Research, 68(7), 2391–2399.
Shah, A. N., et al. (2007). Development and characterization of gemcitabine-resistant pancreatic tumor cells. Annals of Surgical Oncology, 14(12), 3629–3637.
Voulgari, A., & Pintzas, A. (2009). Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et Biophysica Acta, 1796(2), 75–90.
Wang, Z., et al. (2011). Pancreatic cancer: Understanding and overcoming chemoresistance. Nature Reviews Gastroenterology & Hepatology, 8(1), 27–33.
Sabbah, M., et al. (2008). Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resistance Updates, 11(4–5), 123–151.
Arumugam, T., et al. (2009). Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Research, 69(14), 5820–5828.
Hiscox, S., et al. (2006). Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. International Journal of Cancer, 118(2), 290–301.
Kajiyama, H., et al. (2007). Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. International Journal of Oncology, 31(2), 277–283.
Kim, M. R., et al. (2009). Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Science, 100(10), 1834–1841.
Konecny, G. E., et al. (2008). Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. British Journal of Cancer, 98(6), 1076–1084.
Yang, A. D., Fan, F., Camp, E. R., van Buren, G., Liu, W., Somcio, R., et al. (2006). Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clinical Cancer Research, 12(14 Pt 1), 4147–4153. https://doi.org/10.1158/1078-0432.Ccr-06-0038
Fidler, I. J., & Poste, G. (2008) The “seed and soil” hypothesis revisited. The Lancet Oncology, 9(8), 808. https://doi.org/10.1016/s1470-2045(08)70201-8
Li, S., & Li, Q. (2014). Cancer stem cells and tumor metastasis (Review). International Journal of Oncology, 44(6), 1806–1812.
Bernards, R., & Weinberg, R. A. (2002). A progression puzzle. Nature, 418(6900), 823.
Hanniford, D., et al. (2015). A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis. Clinical Cancer Research, 21(21), 4903–4912.
Hunter, K., Welch, D. R., & Liu, E. T. (2003). Genetic background is an important determinant of metastatic potential. Nature Genetics, 34(1), 23–4; author reply 25.
Riester, M., et al. (2017). Distance in cancer gene expression from stem cells predicts patient survival. PLoS One, 12(3), e0173589.
Hermann, P. C., & Heeschen, C. (2013). Metastatic cancer stem cells–quo vadis? Clinical Chemistry, 59(8), 1268–1269.
Lawson, D. A., et al. (2015). Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature, 526(7571), 131–135.
Smith, B. A., et al. (2015). A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proceedings of the National Academy of Sciences, 112(47), E6544–E6552.
Psaila, B., & Lyden, D. (2009). The metastatic niche: Adapting the foreign soil. Nature Reviews Cancer, 9(4), 285–293.
Sceneay, J., Smyth, M. J., & Möller, A. (2013). The pre-metastatic niche: Finding common ground. Cancer and Metastasis Reviews, 32(3–4), 449–464.
Nomura, A., et al. (2015). CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget, 6(10), 8313–8322.
Sampieri, K., & Fodde, R. (2012). Cancer stem cells and metastasis. Seminars in Cancer Biology, 22(3), 187–193.
Gao, W., et al. (2013). Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology, 145(3), 636–46.e5.
Hu, J., et al. (2017). A CD44v(+) subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell Death & Disease, 8(3), e2679.
Gammon, L., et al. (2013). Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One, 8(4), e62493.
Reichert, M., et al. (2018). Regulation of epithelial plasticity determines metastatic organotropism in pancreatic cancer. Developmental Cell, 45(6), 696-711.e8.
Grange, C., et al. (2011). Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Research, 71(15), 5346–5356.
Peinado, H., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883–891.
Costa-Silva, B., et al. (2015). Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biology, 17(6), 816–826.
Adorno-Cruz, V., et al. (2015). Cancer stem cells: Targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Research, 75(6), 924–929.
da Silva-Diz, V., et al. (2018). Cancer cell plasticity: Impact on tumor progression and therapy response. Seminars in Cancer Biology, 53, 48–58.
Foo, J., & Michor, F. (2014). Evolution of acquired resistance to anti-cancer therapy. Journal of Theoretical Biology, 355, 10–20.
Khan, I. N., et al. (2015). Cancer stem cells: A challenging paradigm for designing targeted drug therapies. Drug Discovery Today, 20(10), 1205–1216.
Sørensen, M. D., et al. (2015). Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. Advances in Experimental Medicine and Biology, 853, 111–138.
Fulda, S. (2015). Targeting apoptosis for anticancer therapy. Seminars in Cancer Biology, 31, 84–88.
Koff, J. L., Ramachandiran, S., & Bernal-Mizrachi, L. (2015). A time to kill: Targeting apoptosis in cancer. International Journal of Molecular Sciences, 16(2), 2942–2955.
Xu, X., et al. (2015). Aldehyde dehydrogenases and cancer stem cells. Cancer Letters, 369(1), 50–57.
An, Y., & Ongkeko, W. M. (2009). ABCG2: The key to chemoresistance in cancer stem cells? Expert Opinion on Drug Metabolism & Toxicology, 5(12), 1529–1542.
Dean, M. (2009). ABC transporters, drug resistance, and cancer stem cells. Journal of Mammary Gland Biology and Neoplasia, 14(1), 3–9.
Xu, F., et al. (2014). Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell International, 14(1), 142.
Wang, Y. H., & Scadden, D. T. (2015). Harnessing the apoptotic programs in cancer stem-like cells. EMBO Reports, 16(9), 1084–1098.
Ramasamy, T. S., et al. (2015). Targeting colorectal cancer stem cells using curcumin and curcumin analogues: Insights into the mechanism of the therapeutic efficacy. Cancer Cell International, 15, 96.
Todaro, M., et al. (2010). Colon cancer stem cells: Promise of targeted therapy. Gastroenterology, 138(6), 2151–2162.
Li, X., et al. (2019). Autophagy: A novel mechanism of chemoresistance in cancers. Biomedicine & Pharmacotherapy, 119, 109415.
Sui, X., et al. (2013). Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death & Disease, 4(10), e838.
Yun, C. W., & Lee, S. H. (2018) The roles of autophagy in cancer. International Journal of Molecular Sciences, 19(11). https://doi.org/10.3390/ijms19113466
Ashrafizadeh, M., et al. (2020). Therapeutic effects of kaempferol affecting autophagy and endoplasmic reticulum stress. Phytotherapy Research, 34(5), 911–923.
Janser, F. A., Tschan, M. P., & Langer, R. (2019). The role of autophagy in HER2-targeted therapy. Swiss Medical Weekly, 149, w20138.
Chang, H., & Zou, Z. (2020). Targeting autophagy to overcome drug resistance: Further developments. Journal of Hematology & Oncology, 13(1), 159.
Liu, F., et al. (2013). Effect of autophagy inhibition on chemotherapy-induced apoptosis in A549 lung cancer cells. Oncology Letters, 5(4), 1261–1265.
Luo, M., & Wicha, M. S. (2019). Targeting cancer stem cell redox metabolism to enhance therapy responses. Seminars in Radiation Oncology, 29(1), 42–54.
Snyder, V., et al. (2018). Cancer stem cell metabolism and potential therapeutic targets. Frontiers in Oncology, 8, 203.
Colak, S., & Medema, J. P. (2014). Cancer stem cells–important players in tumor therapy resistance. FEBS Journal, 281(21), 4779–4791.
Macha, M. A., et al. (2017). Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget, 8(13), 20961–20973.
Somasagara, R. R., et al. (2017). RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance. Oncogene, 36(48), 6680–6690.
Steinbichler, T. B., et al. (2018). Therapy resistance mediated by cancer stem cells. Seminars in Cancer Biology, 53, 156–167.
Najafi, M., Farhood, B., & Mortezaee, K. (2019). Cancer stem cells (CSCs) in cancer progression and therapy. Journal of Cellular Physiology, 234(6), 8381–8395.
Prieto-Vila, M., et al. (2017). Drug resistance driven by cancer stem cells and their niche. International Journal of Molecular Sciences, 18(12).
Yeldag, G., Rice, A., & Del Río Hernández, A. (2018). Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers (Basel), 10(12).
Lee, H. H., Bellat, V., & Law, B. (2017). Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer. PLoS One, 12(2), e0171044.
Hu, X., et al. (2012). Induction of cancer cell stemness by chemotherapy. Cell Cycle, 11(14), 2691–2698.
He, K., et al. (2014). Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. International Journal of Cancer, 134(1), 43–54.
Goldman, A., et al. (2015). Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nature Communications, 6, 6139.
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69–80. https://doi.org/10.1016/j.cell.2010.02.027
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
Aguilar, E., et al. (2016). Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program. Stem Cells, 34(5), 1163–1176.
Liu, P. P., et al. (2014). Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death and Differentiation, 21(1), 124–135.
Palorini, R., et al. (2014). Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. Journal of Cellular Biochemistry, 115(2), 368–379.
Bayat Mokhtari, R., et al. (2017). Combination therapy in combating cancer. Oncotarget, 8(23), 38022–38043.
Agliano, A., Calvo, A., & Box, C. (2017). The challenge of targeting cancer stem cells to halt metastasis. Seminars in Cancer Biology, 44, 25–42.
Caras, I. W. (2020). Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model. Stem Cells Translational Medicine, 9(8), 821–826.
Sikic, B. I., et al. (2019). First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. Journal of Clinical Oncology, 37(12), 946–953.
Hasan, M. K., et al. (2018). Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood, 132(2), 170–178.
Choi, M. Y., et al. (2018). Phase I trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell, 22(6), 951-959.e3.
Fisher, R., Pusztai, L., & Swanton, C. (2013). Cancer heterogeneity: Implications for targeted therapeutics. British Journal of Cancer, 108(3), 479–485.
Author information
Authors and Affiliations
Contributions
YK and ZM conceived the study. TN, ZM, RKM, and YK designed the study, contributed to the writing, preparing the tables and figures. All authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics Approval
Not Applicable
Consent to Participate
Not Applicable.
Consent for Publication
All authors have approved the final version of the manuscript and agreed for the publication.
Conflicts of Interest/Competing Interests
The authors report no competing interests. The authors alone are responsible for the content and writing of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Tahsin Nairuz and Zimam Mahmud contributed equally and would be recognized as co-first authors.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nairuz, T., Mahmud, Z., Manik, R.K. et al. Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance. Stem Cell Rev and Rep 19, 1577–1595 (2023). https://doi.org/10.1007/s12015-023-10529-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-023-10529-x